Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Arterial emboli complicating Cisplatin therapy.

Tait CD, Rankin EM.

Case Rep Oncol Med. 2012;2012:276385. doi: 10.1155/2012/276385. Epub 2012 Feb 28.

2.

Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.

Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG.

Int J Gynecol Cancer. 2010 Jul;20(5):772-80.

PMID:
20973267
3.

Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough.

Molassiotis A, Smith JA, Bennett MI, Blackhall F, Taylor D, Zavery B, Harle A, Booton R, Rankin EM, Lloyd-Williams M, Morice AH.

Cough. 2010 Oct 6;6:9. doi: 10.1186/1745-9974-6-9.

4.

Pseudoperipheral palsy due to cortical infarction.

Rankin EM, Rayessa R, Keir SL.

Age Ageing. 2009 Sep;38(5):623-4. doi: 10.1093/ageing/afp025. Epub 2009 Mar 12.

PMID:
19286678
5.

Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.

Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, Snee M, Hatton M, Postmus PE, Collette L, Senan S.

J Clin Oncol. 2009 Jan 1;27(1):78-84. doi: 10.1200/JCO.2008.17.0746. Epub 2008 Dec 1. Erratum in: J Clin Oncol. 2009 Feb 20;27(6):1002.

6.

First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action.

Verborg W, Thomas H, Bissett D, Waterfall J, Steiner J, Cooper M, Rankin EM.

Br J Cancer. 2007 Oct 8;97(7):844-50. Epub 2007 Sep 11.

7.

Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.

Verborg WA, Campbell LR, Highley MS, Rankin EM.

Int J Gynecol Cancer. 2008 Mar-Apr;18(2):228-34. Epub 2007 May 19.

PMID:
17511798
8.

In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide.

Yu J, Paine MJ, Maréchal JD, Kemp CA, Ward CJ, Brown S, Sutcliffe MJ, Roberts GC, Rankin EM, Wolf CR.

Drug Metab Dispos. 2006 Aug;34(8):1386-92. Epub 2006 May 12.

PMID:
16698891
9.

In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer.

Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ.

Drug Metab Dispos. 2006 Apr;34(4):534-8. Epub 2006 Jan 13.

PMID:
16415122
10.

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.

J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.

PMID:
16260696
11.

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, Hatton M, Johnson PW, Martin WM, Rankin EM, James LE, Gregory WM, Qian W, Lee SM.

J Clin Oncol. 2005 Jan 1;23(1):142-53.

PMID:
15625369
12.

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.

Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM.

J Clin Oncol. 2004 Jun 1;22(11):2101-7.

PMID:
15169796
13.

The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.

Ferguson M, Luciani MG, Finlan L, Rankin EM, Ibbotson S, Fersht A, Hupp TR.

Cell Cycle. 2004 Jan;3(1):80-9.

PMID:
14657672
14.

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.

Clin Cancer Res. 2002 Dec;8(12):3676-85.

15.

Modern treatment of ovarian cancer.

Ferguson MJ, Rankin EM.

Scott Med J. 2000 Apr;45(2):37-9. No abstract available.

PMID:
10862434
16.

Clinical and endoscopic features of melanoma metastases in the upper GI tract.

Taal BG, Westerman H, Boot H, Rankin EM.

Gastrointest Endosc. 1999 Aug;50(2):261-3. No abstract available.

PMID:
10425424
17.
18.

Detection of early micrometastases in malignant melanoma.

Rankin EM.

Eur J Cancer. 1996 Sep;32A(10):1627-9. No abstract available.

PMID:
8983265
19.

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.

Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J, Symonds RP.

J Clin Oncol. 1996 Jul;14(7):2113-9.

PMID:
8683244
20.

IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer.

Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, Thomsen LL, Hoekman K, Rankin EM.

J Immunol. 1996 Jan 1;156(1):389-94.

PMID:
8598489
21.

Scientific aspects of gene therapy in melanoma.

Rankin EM.

Curr Opin Oncol. 1995 Mar;7(2):192-6. Review.

PMID:
7756385
22.

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM.

Cancer Immunol Immunother. 1995 Jan;40(1):37-47.

PMID:
7530170
23.

Recombinant interleukin-2 in cancer: basic and clinical aspects.

Vlasveld LT, Rankin EM.

Cancer Treat Rev. 1994 Jul;20(3):275-311. Review. No abstract available.

PMID:
8020007
24.

Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide.

Hoefnagel CA, Rankin EM, Valdés Olmos RA, Israëls SP, Pavel S, Janssen AG.

Eur J Nucl Med. 1994 Jun;21(6):587-8. No abstract available.

PMID:
7915988
25.

Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter.

Vlasveld LT, Rodenhuis S, Rutgers EJ, Dubbelman AC, Hilton AM, Batchelor D, Rankin EM.

Eur J Surg Oncol. 1994 Apr;20(2):122-9.

PMID:
8181576
26.

Report of a symposium on: diagnosis and treatment of cutaneous head and neck melanoma.

Balm AJ, Kroon BB, de Boer JB, Israels SP, Jonk A, Mooi WJ, Neering H, Osterlind A, Rampen FH, Rankin EM, et al.

Eur J Surg Oncol. 1994 Apr;20(2):112-4.

PMID:
7910143
27.

Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer.

Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ, Rankin EM.

Ann Oncol. 1994 Feb;5(2):179-81.

PMID:
8186163
28.

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

Dercksen MW, Hoekman K, ten Bokkel Huinink WW, Rankin EM, Dubbelman R, van Tinteren H, Wagstaff J, Pinedo HM.

Br J Cancer. 1993 Nov;68(5):996-1003.

29.

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, Sein JJ, Dellemijn TA, Rodenhuis S, Melief CJ.

Br J Cancer. 1993 Sep;68(3):559-67.

30.

Ophthalmic toxicity during carboplatin therapy.

Rankin EM, Pitts JF.

Ann Oncol. 1993 Apr;4(4):337-8. No abstract available.

PMID:
8518227
31.

Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.

Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG.

Cancer Immunol Immunother. 1993;36(3):210-3.

PMID:
8439983
32.

Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTG.

Cassidy J, Graham MA, Ten Bokkel Huinink W, McDaniel C, Setanoians A, Rankin EM, Kerr DJ, Kaye SB.

Cancer Chemother Pharmacol. 1993;31(5):395-400.

PMID:
8431974
33.

Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins.

Vlasveld LT, Beijnen JH, Sein JJ, Rankin EM, Melief CJ, Hekman A.

Eur J Cancer. 1993;29A(14):1977-9.

PMID:
8280492
34.

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.

Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, et al.

Lancet. 1992 Aug 8;340(8815):329-33.

PMID:
1353804
35.

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

Vlasveld LT, Rankin EM, Hekman A, Rodenhuis S, Beijnen JH, Hilton AM, Dubbelman AC, Vyth-Dreese FA, Melief CJ.

Br J Cancer. 1992 May;65(5):744-50.

36.

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.

Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan ID, Fullerton W, et al.

Br J Cancer. 1992 Feb;65(2):275-81.

37.

Acute interstitial nephritis during continuous intravenous administration of low-dose interleukin-2.

Diekman MJ, Vlasveld LT, Krediet RT, Rankin EM, Arisz L.

Nephron. 1992;60(1):122-3. No abstract available.

38.

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.

Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye SB, Soukop M, Symonds RP, Reed NS, Rankin EM.

J Clin Oncol. 1991 Feb;9(2):295-304.

PMID:
1988576
39.

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.

Jones RD, Kerr DJ, Harnett AN, Rankin EM, Ray S, Kaye SB.

Br J Cancer. 1990 Jul;62(1):133-5.

40.

The myelotoxicity of carboplatin is influenced by the time of its administration.

Kerr DJ, Lewis C, O'Neil B, Lawson N, Blackie RG, Newell DR, Boxall F, Cox J, Rankin EM, Kaye SB.

Hematol Oncol. 1990 Jan-Feb;8(1):59-63.

PMID:
2404843
41.

Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer.

Lewis C, Lawson N, Rankin EM, Morrison G, MacLean AB, Cordiner J, Cassidy J, Kerr DJ, Kaye SB.

Cancer Chemother Pharmacol. 1990;26(4):283-7.

PMID:
1695127
42.

Metastatic vipoma arising from colonic primary tumour.

Bradley C, Haddock G, Pickard RG, Rankin EM.

Eur J Surg Oncol. 1989 Aug;15(4):386-9.

PMID:
2547666
43.

Autonomic neuropathy following treatment with flavone acetic acid.

Lewis CR, Jardine A, Rankin EM, Kaye SB.

Eur J Cancer Clin Oncol. 1989 Mar;25(3):573-4. No abstract available.

PMID:
2703010
44.

Phase I clinical and pharmacokinetic study of LY 195448.

Cassidy J, Lewis C, Adams L, Setanoians A, Bayssas M, Boder GG, Rankin EM, Kaye SB.

Cancer Chemother Pharmacol. 1989;24(4):233-7.

PMID:
2752504
45.

Hypersensitivity reaction to epirubicin.

Cassidy J, Rankin EM.

Med Oncol Tumor Pharmacother. 1989;6(4):297-8.

PMID:
2615533
46.

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

Cassidy J, Raina V, Lewis C, Adams L, Soukop M, Rapeport WG, Zussman BD, Rankin EM, Kaye SB.

Br J Cancer. 1988 Nov;58(5):651-3.

47.

Transcatheter embolisation to control severe bleeding in fungating breast cancer.

Rankin EM, Rubens RD, Reidy JF.

Eur J Surg Oncol. 1988 Feb;14(1):27-32.

PMID:
3345852
48.

Phase I and pharmacokinetic study of flavone acetic acid.

Kerr DJ, Kaye SB, Cassidy J, Bradley C, Rankin EM, Adams L, Setanoians A, Young T, Forrest G, Soukop M, et al.

Cancer Res. 1987 Dec 15;47(24 Pt 1):6776-81.

49.

Low back pain and cancer.

Woll PJ, Rankin EM.

Br Med J (Clin Res Ed). 1987 Nov 14;295(6608):1278. No abstract available.

50.

Phase II trial of prednimustine as first-line chemotherapy in patients with advanced breast cancer.

Rankin EM, Harvey C, Knight RK, Rubens RD.

Cancer Treat Rep. 1987 Nov;71(11):1107-8. No abstract available.

PMID:
3119205

Supplemental Content

Loading ...
Support Center